Floatz logo

Vinorelbine

Gliosarcoma

National Cancer Institute (NCI)Phase 2/3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

38 Active assets in the Gliosarcoma cohort.

Asset / SponsorPhaseRating
Irinotecan
RTOG Foundation, Inc.
Phase 3BB
(+)-VINCRISTINE
RTOG Foundation, Inc.
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
Nivolumab
Andrew P. Groves
Phase 2/3BB
Rindopepimut
Celldex Therapeutics
Phase 3BB

View all 50 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →